Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling

• Published in: Journal of experimental & clinical cancer research Vol. 36; no. 1; p. 153
• Main Authors: Tian, Jing, Wang, Yong, Zhang, Xing, Ren, Qianyao, Li, Rong, Huang, Yue, Lu, Huiling, Chen, Jian
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.11.2017; BioMed Central; BMC
• Subjects: Animals; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - pharmacology; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Calycosin; Cancer cells; Cell growth; Cell Line, Tumor; Cell Proliferation - drug effects; Cellular signal transduction; Development and progression; Drug therapy; Epidermal growth factor; Estrogens; Experiments; Female; Gene expression; Gene Expression Regulation, Neoplastic - drug effects; Genetic aspects; GPR30; Growth; Humans; Isoflavones - administration & dosage; Isoflavones - pharmacology; Kinases; Long non-coding RNA; MCF-7 Cells; Medical research; Mice; Physiological aspects; Proteins; Receptors, Estrogen - genetics; Receptors, Estrogen - metabolism; Receptors, G-Protein-Coupled - genetics; Receptors, G-Protein-Coupled - metabolism; RNA, Long Noncoding - genetics; Signal Transduction - drug effects; Studies; Up-Regulation; WDR7-7; Xenograft Model Antitumor Assays; China; United States > US; GPR30; Breast cancer; Calycosin; WDR7-7; Long non-coding RNA

Clinically, breast cancer is generally classified into estrogen receptor-positive (ER+) or estrogen receptor-negative (ER-) subtypes. The phytoestrogen calycosin has been shown to inhibit the proliferation of ER+ cells, which may be mediated by a feedback loop that involves miR-375, RAS dexamethason...